| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 00% | ₹1,324.6 0% | 4,400 | ₹7.05 0% | 00% |
| 00% | ₹1,229.9 0% | 4,500 | ₹5.85 -26.87% | 7,500-7.69% |
| 00% | ₹1,136.65 0% | 4,600 | ₹8.05 0% | 1,5000% |
| 00% | ₹585.95 0% | 4,650 | ₹22.35 0% | 00% |
| 1250% | ₹598.05 0% | 4,700 | ₹12.45 -23.38% | 1,625-7.14% |
| 00% | ₹701.05 0% | 4,750 | ₹13.25 -33.41% | 625-16.66% |
| 1250% | ₹460 9.52% | 4,800 | ₹17.8 -28.94% | 7,62596.77% |
| 00% | ₹617.25 0% | 4,850 | ₹23 -27.67% | 4,250112.5% |
| 00% | ₹870.15 0% | 4,900 | ₹26.65 -25.35% | 3,375285.71% |
| 00% | ₹538.05 0% | 4,950 | ₹35.4 227.77% | 750500% |
| 00% | ₹787.25 0% | 5,000 | ₹45.85 -26.34% | 12,2505.37% |
| 00% | ₹464.25 0% | 5,050 | ₹57.95 -28.27% | 5,7502.22% |
| 00% | ₹708 0% | 5,100 | ₹74.35 -24.7% | 14,125-8.13% |
| 7,0001766.66% | ₹169.75 14.73% | 5,150 | ₹91.35 -19.37% | 7,250544.44% |
| 17,875-18.75% | ₹152.6 32.4% | 5,200 | ₹114 -20.55% | 31,125-10.75% |
| 8,37515.51% | ₹132.3 41.12% | 5,250 | ₹125 -23.71% | 6,500-14.75% |
| 16,500-12% | ₹103.2 38.06% | 5,300 | ₹164 -18.2% | 14,625-1.68% |
| 7500% | ₹153.5 0% | 5,350 | ₹244.45 0% | 1,0000% |
| 33,250-30.72% | ₹66 36.36% | 5,400 | ₹179.65 0% | 3,3750% |
| 7,62545.23% | ₹52.3 36.55% | 5,450 | ₹110 0% | 2500% |
| 23,625-25.29% | ₹39.95 30.34% | 5,500 | ₹235 0% | 1,8750% |
| 2,375137.5% | ₹31.35 29.01% | 5,550 | ₹311.65 0% | 00% |
| 5,12517.14% | ₹26.7 36.92% | 5,600 | ₹400 0% | 00% |
| 1,875400% | ₹21.25 20.05% | 5,650 | ₹374.25 0% | 00% |
| 7,875-14.86% | ₹16.8 34.93% | 5,700 | ₹440.7 0% | 2500% |
| 2,000-52.94% | ₹12.15 14.62% | 5,750 | ₹465 0% | 1250% |
| 1,75016.66% | ₹7.5 -18.91% | 5,800 | ₹343.5 0% | 00% |
| 625400% | ₹9.55 -70.15% | 5,850 | ₹516.15 0% | 00% |
| 2,6250% | ₹7.2 0% | 5,900 | ₹400.9 0% | 00% |
| 2,250-5.26% | ₹6 2.56% | 6,000 | ₹602.95 0% | 1250% |
| 00% | ₹172.6 0% | 6,100 | ₹529.45 0% | 00% |
| 00% | ₹144.65 0% | 6,200 | ₹600.05 0% | 00% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
